CRP and acute coronary syndrome: Regarding the other study variables, considering that vascular inflammation is a fundamental mechanism in the progression of atherosclerosis and acute coronary syndromes [60], CRP stands out as an inflammation biomarker and is recommended as a secondary risk assessment factor in treatment decision-making [61, 62], particularly with regard to the treatment of high blood cholesterol [63, 64].